See more : Bonus BioGroup Ltd. (BBIXF) Income Statement Analysis – Financial Results
Complete financial analysis of DIAGNOS Inc. (DGNOF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DIAGNOS Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- Giantec Semiconductor Corporation (688123.SS) Income Statement Analysis – Financial Results
- Tana Resources Corp. (TANA.CN) Income Statement Analysis – Financial Results
- Assicurazioni Generali S.p.A. (GEN.BR) Income Statement Analysis – Financial Results
- PETRONAS Gas Berhad (PNAGF) Income Statement Analysis – Financial Results
- AIB Group plc (AIBRF) Income Statement Analysis – Financial Results
DIAGNOS Inc. (DGNOF)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.diagnos.ca
About DIAGNOS Inc.
DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. The company was founded in 1998 and is headquartered in Brossard, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 170.16K | 438.83K | 267.07K | 331.52K | 326.47K | 326.47K | 1.61M | 2.39M | 981.48K | 564.18K | 2.70M | 1.51M | 1.33M | 1.07M | 358.07K | 1.89M | 1.86M | 775.72K | 709.19K | 111.75K | 387.72K | 128.62K | 7.00K |
| Cost of Revenue | 1.01M | 857.13K | 614.60K | 804.97K | 1.09M | 1.09M | 1.32M | 1.67M | 1.18M | 1.11M | 2.24M | 1.02M | 104.54K | 24.95K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -837.94K | -418.30K | -347.53K | -473.46K | -759.37K | -759.37K | 290.90K | 719.10K | -203.51K | -541.43K | 464.53K | 490.00K | 1.22M | 1.05M | 358.07K | 1.89M | 1.86M | 775.72K | 709.19K | 111.75K | 387.72K | 128.62K | 7.00K |
| Gross Profit Ratio | -492.45% | -95.32% | -130.13% | -142.81% | -232.60% | -232.60% | 18.04% | 30.09% | -20.73% | -95.97% | 17.17% | 32.47% | 92.13% | 97.68% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 1.08M | 603.35K | 0.00 | 0.00 | 0.00 | 922.49K | 0.00 | 1.18M | 1.07M | 1.31M | 1.00M | 831.56K | 793.96K | 614.13K | 618.21K | 674.24K | 193.82K | 101.25K | 179.58K | 784.10K | -4.56K | 192.92K | 1.44M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.84M | 2.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -293.72K | -295.66K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.77M | 2.24M | 1.94M | 2.32M | 2.17M | 2.17M | 2.76M | 2.69M | 2.52M | 2.13M | 2.11M | 2.55M | 2.46M | 2.10M | 1.69M | 3.23M | 2.02M | 1.39M | 1.09M | 1.10M | 426.23K | 567.04K | 1.45M |
| Other Expenses | 0.00 | 100.14K | 264.28K | 85.80K | 52.31K | 52.31K | 0.00 | 0.00 | 1.07M | 0.00 | 0.00 | -374.80K | -240.63K | -204.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.76M | 2.24M | 1.94M | 2.32M | 2.17M | 2.17M | 2.76M | 2.69M | 2.52M | 2.13M | 2.11M | 2.55M | 3.15M | 2.66M | 2.28M | 4.04M | 2.29M | 1.52M | 1.30M | 1.91M | 496.73K | 899.32K | 3.06M |
| Cost & Expenses | 3.86M | 3.10M | 2.55M | 3.13M | 3.26M | 3.26M | 4.08M | 4.36M | 3.70M | 3.23M | 4.35M | 3.56M | 3.25M | 2.69M | 2.28M | 4.04M | 2.29M | 1.52M | 1.30M | 1.91M | 496.73K | 899.32K | 3.06M |
| Interest Income | 6.89K | 5.38K | 5.38K | 3.23K | 3.23K | 1.48K | 0.00 | 0.00 | 0.00 | 0.00 | 5.23K | 11.89K | 27.01K | 8.79K | 15.44K | 76.43K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 550.17K | 53.78K | 32.16K | 347.11K | 1.03M | 1.03M | 827.77K | 955.38K | 469.22K | 159.40K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 47.25K | 0.00 | 0.00 |
| Depreciation & Amortization | 124.21K | 101.17K | 105.80K | 92.84K | 101.72K | 191.32K | 230.19K | 192.65K | 82.37K | 43.71K | 62.19K | 89.52K | 81.36K | 125.94K | 186.17K | 188.36K | 79.67K | 32.68K | 29.28K | 23.66K | 75.05K | 139.36K | 176.19K |
| EBITDA | -2.45M | -2.10M | -2.45M | -2.61M | -2.69M | -2.69M | -2.66M | -1.78M | -2.64M | -2.62M | -1.58M | -1.97M | -1.84M | -1.49M | -1.74M | -1.97M | -347.40K | -711.98K | -560.21K | -1.77M | -33.96K | -631.34K | -2.88M |
| EBITDA Ratio | -1,437.61% | -557.99% | -723.29% | -785.96% | -822.85% | -822.39% | -164.64% | -74.54% | -269.07% | -465.19% | -58.55% | -130.30% | -134.65% | -184.81% | -485.96% | -104.35% | -18.65% | -91.78% | -78.99% | -1,587.96% | -8.76% | -490.86% | -41,123.96% |
| Operating Income | -3.69M | -2.55M | -2.02M | -2.71M | -2.88M | -2.88M | -2.89M | -1.97M | -2.72M | -2.67M | -1.65M | -2.06M | -2.22M | -1.58M | -1.93M | -2.16M | -427.07K | -744.66K | -589.49K | -1.80M | -109.01K | -770.70K | -3.05M |
| Operating Income Ratio | -2,168.30% | -582.10% | -756.03% | -816.65% | -881.45% | -881.00% | -178.91% | -82.60% | -277.46% | -472.94% | -60.85% | -136.23% | -167.19% | -147.33% | -537.96% | -114.34% | -22.92% | -96.00% | -83.12% | -1,609.13% | -28.12% | -599.21% | -43,640.96% |
| Total Other Income/Expenses | 568.95K | -259.14K | 608.66K | 232.12K | -505.21K | -1.03M | -622.77K | 232.83K | 475.50K | -159.40K | 5.23K | 11.89K | 27.01K | 275.63K | 0.00 | 0.00 | 0.00 | 124.41K | 8.37K | 64.85K | 26.20K | -57.70K | -123.17K |
| Income Before Tax | -3.12M | -2.61M | -2.05M | -3.38M | -3.90M | -3.90M | -3.09M | -2.93M | -3.19M | -2.83M | -1.64M | -2.04M | -2.19M | -1.31M | 0.00 | 0.00 | 0.00 | -620.25K | -581.12K | -1.73M | -82.81K | -828.40K | -3.18M |
| Income Before Tax Ratio | -1,833.93% | -594.35% | -768.07% | -1,020.42% | -1,195.74% | -1,195.74% | -191.55% | -122.57% | -325.27% | -501.19% | -60.66% | -135.44% | -165.16% | -121.68% | 0.00% | 0.00% | 0.00% | -79.96% | -81.94% | -1,551.10% | -21.36% | -644.07% | -45,400.57% |
| Income Tax Expense | 0.00 | 153.92K | 296.44K | 432.91K | -64.67K | -64.67K | -192.19K | -1.32M | 0.00 | 0.00 | 0.00 | -540.22K | 28.02K | -508.81K | -15.44K | -76.43K | -28.99K | -3.12K | 747.00 | 12.79K | 47.25K | -33.48K | 4.58K |
| Net Income | -3.12M | -2.61M | -2.05M | -3.38M | -3.84M | -3.84M | -2.90M | -2.93M | -3.19M | -2.83M | -1.64M | -2.04M | -2.19M | -1.31M | -1.91M | -2.08M | -398.09K | -617.13K | -581.86K | -1.75M | -130.06K | -762.98K | -3.18M |
| Net Income Ratio | -1,833.93% | -594.35% | -768.07% | -1,020.42% | -1,175.93% | -1,175.93% | -179.63% | -122.57% | -325.27% | -501.19% | -60.66% | -135.44% | -165.16% | -121.68% | -533.64% | -110.28% | -21.37% | -79.56% | -82.05% | -1,562.55% | -33.54% | -593.21% | -45,465.96% |
| EPS | -0.04 | -0.04 | -0.03 | -0.05 | -0.09 | -0.20 | -0.17 | -0.24 | -0.30 | -0.29 | -0.21 | -0.31 | -0.35 | -0.25 | -0.40 | -0.46 | -0.10 | -0.17 | -0.18 | -0.65 | -0.09 | -0.71 | -1.06 |
| EPS Diluted | -0.04 | -0.04 | -0.03 | -0.05 | -0.09 | -0.20 | -0.17 | -0.24 | -0.30 | -0.29 | -0.21 | -0.31 | -0.35 | -0.25 | -0.40 | -0.46 | -0.10 | -0.17 | -0.18 | -0.65 | -0.09 | -0.71 | -1.06 |
| Weighted Avg Shares Out | 72.82M | 69.62M | 68.73M | 63.11M | 40.74M | 18.84M | 16.89M | 12.37M | 10.62M | 9.85M | 7.78M | 6.58M | 6.20M | 5.23M | 4.80M | 4.56M | 4.07M | 3.62M | 3.15M | 2.68M | 1.41M | 1.07M | 3.00M |
| Weighted Avg Shares Out (Dil) | 72.82M | 69.62M | 68.73M | 63.11M | 40.74M | 18.84M | 16.89M | 12.37M | 10.62M | 9.85M | 7.78M | 6.58M | 6.20M | 5.23M | 4.80M | 4.56M | 4.07M | 3.62M | 3.15M | 2.68M | 1.41M | 1.07M | 3.00M |
DIAGNOS Welcomes Mr. Michael Braeuel to its Board of Directors
BROSSARD, Quebec, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, is pleased to announce...
DIAGNOS Announces Closing of First Tranche of Private Placement
BROSSARD, Quebec, Feb. 27, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, announces the closing of...
Diagnos Announces Variation in One Insider Ownership of Common Shares
BROSSARD, Québec, Feb. 23, 2024 (GLOBE NEWSWIRE) -- In accordance with regulatory requirements, Diagnos Inc. (“DIAGNOS”, the “Corporation” or the “Issuer”) (TSX Venture: ADK), announces that on February 20, 2024, Mr. Tristram Coffin (the “Investor”) disposed of 800,000 common shares...
DIAGNOS recognized as a Top TSX Venture Exchange Company
BROSSARD, Quebec, Feb. 21, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through its FLAIRE platform based on Artificial Intelligence (AI), is proud to...
DIAGNOS Appoints New Chief Operating Officer
BROSSARD, Quebec, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, is pleased to announce...
DIAGNOS Secures Exclusive Distribution Agreement for Canada with EssilorLuxottica, a Global Leader in Vision Care
BROSSARD, Quebec, Dec. 11, 2023 (GLOBE NEWSWIRE) -- DIAGNOS Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through its FLAIRE platform based on Artificial Intelligence (AI), is thrilled to...
DIAGNOS Announces Closing of Private Placement
BROSSARD, Québec, Dec. 04, 2023 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a Canadian corporation active in early detection of critical health issues through the use of its FLAIRE platform based on Artificial...
DIAGNOS AI Retina Analysis is being deployed across Canada's Largest Specialist Care Provider in Diabetes & Endocrinology
BROSSARD, Quebec, Oct. 05, 2023 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a Canadian corporation active in early detection of critical health issues through the use of its FLAIRE platform based on Artificial...
DIAGNOS Announces Closing of Private Placement and Exercise
BROSSARD, Quebec, May 18, 2023 (GLOBE NEWSWIRE) — DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a Canadian corporation active in early detection of critical health issues through the use of its FLAIRE platform based on Artificial...
DIAGNOS and ETS to Present Ground-breaking Research on Mass Screening for Macular Edema at ARVO 2023
BROSSARD, Quebec, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS”, the “Corporation” or ”we”) (TSX Venture: ADK) (OTCQB: DGNOF) is a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial...
Source: https://incomestatements.info
Category: Stock Reports